Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

ABT 2026 Q1

For the quarter ended March 31, 2026, Abbott reported sales growth led by medical devices, established pharmaceuticals, and diagnostics, while nutrition declined; management updated its full-year outlook to include the completed Exact Sciences acquisition.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine.
  • The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics.
  • Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

Risks that still need monitoring

  • Nutrition weakness

    Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

  • Exact Sciences integration

    The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized.

  • Infant-formula litigation

    Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

Primary sources

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/16/2026, 12:00:00 AM

Open original source
Abbott Investor RelationsAbbott Laboratories · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Abbott Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source

Continue research

Open risk researchReturn to full stock research